No abstract

No abstract

Objective: To describe, synthesize, and interpret literature on the role of poly (ADP-ribose) polyermase inhibitors in the treatment of endometrial cancer and to identify areas of interest for future reasearch.Design: Scoping review of the literature covering several study designs. Results: 96 records were identified after searching the literature and 69 records were subsequently reviewed.Conclusion: There is conflicting evidence regarding the utility of proposed biomarkers in predicting sensitivity of endometrial cancer to PARP inhibitor treatment. Current in vitro and in vivo studies suggest that PARP inhibitors may be effective in the treatment of certain subsets of endometrial cancer, but further research is warranted.